Income from Continuous Operations: A company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change.
Esperion Therapeutics, Inc. (ESPR) had Income from Continuous Operations of $61.83M for the most recently reported fiscal quarter, ending 2025-12-31.
| Income Statement Financials | |
$168.45M |
|
$61.83M |
|
$27.85M |
|
$140.59M |
|
$83.21M |
|
$85.23M |
|
$-21.56M |
|
$63.67M |
|
$63.67M |
|
$61.83M |
|
|
Income from Continuous Operations |
$61.83M |
$61.83M |
|
$61.83M |
|
$85.23M |
|
$85.90M |
|
207.87M |
|
207.87M |
|
$0.32 |
|
$0.32 |
|
| Balance Sheet Financials | |
$462.57M |
|
$0.34M |
|
$3.32M |
|
$465.89M |
|
$300.81M |
|
$249.48M |
|
$467.04M |
|
$767.85M |
|
$-301.96M |
|
$-302.02M |
|
$-301.96M |
|
245.22M |
|
| Cash Flow Statement Financials | |
$-13.09M |
|
-- |
|
$36.18M |
|
$144.76M |
|
$167.85M |
|
$23.09M |
|
$9.87M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
1.54 |
|
-- |
|
-- |
|
-4.75 |
|
-0.83 |
|
83.46% |
|
50.60% |
|
50.60% |
|
-- |
|
37.80% |
|
36.71% |
|
$-13.09M |
|
-- |
|
-- |
|
-- |
|
0.36 |
|
0.27 |
|
1.20 |
|
74.90 |
|
-20.48% |
|
-20.47% |
|
13.27% |
|
-117.80% |
|
$-1.23 |
|
$-0.06 |
|
$-0.06 |
|